Table 5 Ongoing randomized phase II and phase III Trials in Early and Locally Advanced NSCLC
From: Lung cancer immunotherapy: progress, pitfalls, and promises
Neoadjuvant Strategy | Trial Identifier (NCT reference) | Phase | Drug/Treatment |
|---|---|---|---|
IB-IIIA | CheckMate 816 (NCT 02,998,528) | III | Nivo + Ipi vs. chemotherapy |
IIIA | (NCT03081689) | II | Nivo + chemotherapy |
IB (> 3 cm)-IIIA | TOP 1501 (NCT02818920) | II | Pembro |
IB (> 4 cm)-IIIA | PRINCEPS (NCT02994576) | II | Atezo |
IB-IIIA | MAC (NCT02716038) | II | Atezo + chemotherapy |
I (> 2 cm)-IIIA | (NCT02904954) | II | Durva or Durva + SRBT |
IB(> 4 cm)-IIIA | ANVIL (NCT 02,595,944) | III | Nivo vs Obs |
IB(> 4 cm)-IIIA | PEARLS(NCT02504372) | III | Pembro vs. placebo |
IB(> 4 cm)-IIIA | IMpower010(NCT02486718) | III | Atezo vs. BSC |
IB(> 4 cm)-IIIA | BR-31(NCT02273375) | III | Durva vs. placebo |
Unresectable III A/B | RTOG3505(NCT02768558) | III | CRT Nivo vs. placebo |
Early stage unresected NSCLC | NCT03833154 | III | Durvalumab + SBRT vs placebo + SBRT vs Osimertinib + SBRT |
 IIA- IIIB NSCLC | ALCHEMIST (NCT04267848) | III | Pembrolizumab + chemotherapy |
Early stage NSCLC | CANOPY-N(NCT03968419) | II | Canakinumab ± Pembro |
 III-IV NSCLC | NCT03793179 | III | Pembro ± chemotherapy |
 III-IV NSCLC | IGNYTE(NCT03767348) | II | RP 1 ± Nivolumab |
PD-L1 expressing NSCLC | NCT04432207 | I | IMU-201 (PD1-Vaxx) |
 III-IV NSCLC | NCT04007744 | I | Pembro + Sonidegib |